Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
TPST
vs
S&P 500
TPST
S&P 500
Over the past 12 months, TPST has underperformed S&P 500, delivering a return of -94% compared to S&P 500's +14% growth.
Stocks Performance
TPST vs S&P 500
Performance Gap
TPST vs S&P 500
Performance By Year
TPST vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Tempest Therapeutics Inc
Glance View
Tempest Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its main work is to discover and test small-molecule drugs that are designed to change how tumors grow, survive, and interact with the immune system. The company does not sell a broad line of products; its business is built around advancing a small number of drug candidates through clinical trials. The company’s customers are not patients directly. Instead, it works with hospitals, doctors, research sites, regulators, and eventually larger drugmakers that may license, partner on, or buy its programs. Tempest makes money, when it succeeds, through collaboration payments, licensing deals, and other commercialization arrangements tied to its drug pipeline rather than from routine product sales. What makes Tempest different is its role as an early-stage drug developer in a very high-risk part of the healthcare industry. It focuses on finding cancer treatments with novel biological targets and moving them through the long testing process that determines whether a drug can become an approved therapy. In practice, Tempest is a research and development company whose value depends on the progress of its experimental medicines.